Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Regeneron Pharmaceuticals
Modality
nucleic_acid
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06024408CT.gov A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Inherited Disease Susceptibility
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Aln-Pnp (this asset) | Regeneron Pharmaceuticals | P1 | CC · 47 |
| Cephalexin | University of California, San Francisco | P2 | CCC |
| Minoxidil | Duke University | P1 | CC |
| Posaconazole | Bochud Pierre-Yves | N/A | D |
| Blood, Whole | University Hospital, Lille | Unk | D |
| Fluconazole | Bochud Pierre-Yves | N/A | D |
Other indications for Aln-Pnp
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P2 | BB · 65 |
| Metabolic Dysfunction-Associated Steatohepatitis | — | P1 | CC · 47 |
| Head And Neck Cancer | — | P1 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Aln-Pnp in Inherited Disease Susceptibility. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/aln-pnp-inherited-disease-susceptibility
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →